Suchen
Abcellera Biologics Inc
ABCLZur Watchlist hinzufügen
4.090USD
-0.310-7.05%
Handelsschluss 05/15, 16:00（ET）Kurse um 15 Minuten verzögert
1.24BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Abcellera Biologics Inc Unternehmen
AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. It is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs.
Abcellera Biologics Inc Informationen
BörsenkürzelABCL
Name des UnternehmensAbcellera Biologics Inc
IPO-datumDec 11, 2020
CEOHansen (Carl L.G)
Anzahl der mitarbeiter596
WertpapierartOrdinary Share
GeschäftsjahresendeDec 11
Addresse150 W 4Th Avenue
StadtVANCOUVER
BörseNASDAQ OMX - NASDAQ BASIC
LandCanada
PostleitzahlV5Y 1G6
Telefon16045599005
Websitehttps://www.abcellera.com/
BörsenkürzelABCL
IPO-datumDec 11, 2020
CEOHansen (Carl L.G)
Führungskräfte von Abcellera Biologics Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Veronique Lecault, Ph.D.
Dr. Veronique Lecault, Ph.D.
Co-Founder, Chief Operating Officer, Director
Co-Founder, Chief Operating Officer, Director
9.61M
--
Mr. Andrew Booth
Mr. Andrew Booth
Chief Financial Officer
Chief Financial Officer
326.56K
+13.05%
Dr. Carl L.G. Hansen, Ph.D.
Dr. Carl L.G. Hansen, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
--
--
Mr. Tryn T. Stimart, J.D.
Mr. Tryn T. Stimart, J.D.
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
--
--
Dr. Michael R. Hayden
Dr. Michael R. Hayden
Lead Independent Director
Lead Independent Director
--
--
Mr. John S. Montalbano
Mr. John S. Montalbano
Independent Director
Independent Director
--
--
Dr. Sarah B. Noonberg, M.D., Ph.D.
Dr. Sarah B. Noonberg, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Stephen Quake
Mr. Stephen Quake
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Veronique Lecault, Ph.D.
Dr. Veronique Lecault, Ph.D.
Co-Founder, Chief Operating Officer, Director
Co-Founder, Chief Operating Officer, Director
9.61M
--
Mr. Andrew Booth
Mr. Andrew Booth
Chief Financial Officer
Chief Financial Officer
326.56K
+13.05%
Dr. Carl L.G. Hansen, Ph.D.
Dr. Carl L.G. Hansen, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
--
--
Mr. Tryn T. Stimart, J.D.
Mr. Tryn T. Stimart, J.D.
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
--
--
Dr. Michael R. Hayden
Dr. Michael R. Hayden
Lead Independent Director
Lead Independent Director
--
--
Mr. John S. Montalbano
Mr. John S. Montalbano
Independent Director
Independent Director
--
--
Umsatzaufteilung
Währung: USDAktualisiert: Mon, Apr 6
Währung: USDAktualisiert: Mon, Apr 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2024Q2
FY2023Q2
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Licensing revenue
46.92M
62.45%
Research fees
27.21M
36.22%
Milestone payments
1.00M
1.33%
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Licensing revenue
46.92M
62.45%
Research fees
27.21M
36.22%
Milestone payments
1.00M
1.33%
Aktionärsstatistik
Aktualisiert: Thu, May 14
Aktualisiert: Thu, May 14
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Thermopylae Holdings Ltd
18.38%
Baker Bros. Advisors LP
9.01%
Capital World Investors
4.38%
Two Sigma Investments, LP
3.52%
Lecault (Veronique)
3.15%
Andere
61.56%
Aktionäre
Aktionäre
Anteil
Thermopylae Holdings Ltd
18.38%
Baker Bros. Advisors LP
9.01%
Capital World Investors
4.38%
Two Sigma Investments, LP
3.52%
Lecault (Veronique)
3.15%
Andere
61.56%
Aktionärstypen
Aktionäre
Anteil
Corporation
18.39%
Hedge Fund
15.77%
Investment Advisor
11.92%
Research Firm
4.81%
Investment Advisor/Hedge Fund
4.44%
Individual Investor
4.22%
Bank and Trust
1.47%
Venture Capital
0.15%
Pension Fund
0.13%
Andere
38.70%
Institutionelle Beteiligung
Aktualisiert: Sun, Apr 5
Aktualisiert: Sun, Apr 5
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2026Q1
323
131.69M
43.14%
-19.22M
2025Q4
315
112.27M
50.73%
-101.09K
2025Q3
340
112.51M
51.75%
-3.28M
2025Q2
368
115.12M
53.94%
-18.45M
2025Q1
420
133.63M
52.62%
-23.37M
2024Q4
441
121.95M
50.14%
+4.83M
2024Q3
440
121.95M
51.59%
-4.54M
2024Q2
439
127.07M
51.27%
-6.55M
2024Q1
432
134.44M
53.43%
-22.43M
2023Q4
425
138.44M
60.93%
-1.40M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Thermopylae Holdings Ltd
56.13M
18.52%
+215.46K
+0.39%
Feb 27, 2026
Baker Bros. Advisors LP
27.53M
9.08%
--
--
Dec 31, 2025
Capital World Investors
13.36M
4.41%
--
--
Dec 31, 2025
Two Sigma Investments, LP
10.76M
3.55%
+769.18K
+7.70%
Dec 31, 2025
Lecault (Veronique)
9.61M
3.17%
--
--
Apr 01, 2025
UBS Asset Management (Americas) LLC
5.00M
1.65%
+5.00M
--
Dec 31, 2025
Goldman Sachs & Company, Inc.
4.34M
1.43%
+4.09M
+1636.29%
Dec 31, 2025
UBS Switzerland AG
1.93M
0.64%
-540.41K
-21.86%
Dec 31, 2025
ArrowMark Colorado Holdings, LLC
4.11M
1.35%
--
--
Dec 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
iShares Genomics Immunology and Healthcare ETF
2.64%
Virtus LifeSci Biotech Clinical Trials ETF
1.19%
ProShares Ultra Nasdaq Biotechnology
0.16%
Invesco Nasdaq Biotechnology ETF
0.16%
SPDR S&P International Small Cap ETF
0.12%
iShares Biotechnology ETF
0.11%
Invesco RAFI Developed Mkts ex-US SM ETF
0.05%
Avantis US Small Cap Equity ETF
0.01%
SPDR Portfolio Developed World ex-US ETF
0.01%
Fidelity Nasdaq Composite Index ETF
0.01%
Mehr Anzeigen
iShares Genomics Immunology and Healthcare ETF
Anteil2.64%
Virtus LifeSci Biotech Clinical Trials ETF
Anteil1.19%
ProShares Ultra Nasdaq Biotechnology
Anteil0.16%
Invesco Nasdaq Biotechnology ETF
Anteil0.16%
SPDR S&P International Small Cap ETF
Anteil0.12%
iShares Biotechnology ETF
Anteil0.11%
Invesco RAFI Developed Mkts ex-US SM ETF
Anteil0.05%
Avantis US Small Cap Equity ETF
Anteil0.01%
SPDR Portfolio Developed World ex-US ETF
Anteil0.01%
Fidelity Nasdaq Composite Index ETF
Anteil0.01%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
